Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product
As You Can See Everything turns Billy Evans into the year’s most unlikely documentary villain, his Austin startup Haemanthus faces a simple question: What has it built?
What it means
- What to watch: When results disappoint, the next round of analyst estimate cuts is often the bigger move.
- Timing: It landed over the weekend, so Monday's session is the first that could react.
The bigger picture
With earnings, the number matters less than the number versus expectations — and guidance often matters more than both. A beat paired with a soft outlook can still get a cold reception. With no company named, any effect tends to surface first in the indexes, Treasury yields and the dollar, which the Markets page tracks live.
What to watch next
With no company named, the backdrop above is the thread to pull, and the Markets page shows how the indexes are taking it. If it touches a company you follow, that company's page carries the prices and coverage this one cannot. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. Wook AI, up top, can look up any company the story touches and pull its live figures — no tab-hopping required.
How this analysis was made
Fortune published it, and Wook filed it under Earnings. It reads bearish at medium severity because of “miss” in the wording, with nothing on the bullish side to offset it. No company could be matched, so there are no prices beside it — common for policy and macro stories, which move markets through rates, currencies and sentiment rather than one balance sheet. The preview above is the publisher's own wording.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.